Oscar Tahuahua/X
May 4, 2025, 02:34
Oscar Tahuahua: Rational combos and next-gen RAS inhibitors are key
Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, shared on X about a recent paper by Richard Y. Ebright et al. published in Cancer Discovery:
“RAS Inhibition: Response and Resistance
– Primary (10–20%): KEAP1, PI3K, TP53, SMARCA4 mutations.
– Acquired (~60%): KRAS muts (25–30%), RTKs (20–25%), PI3K (10–15%), MYC, EMT and MAPK pathway.
Rational combos and next-gen RAS inhibitors are key.”
Response and Resistance to RAS Inhibition in Cancer
Authors: Richard Y. Ebright et al
Learn more about RAS pathway in cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 4, 2025, 02:34
May 4, 2025, 01:29
May 4, 2025, 01:19